COVIran Barekat

Last updated
COVIran Barekat
COVIran Barakat.jpg
A vial of COVIran Barakat
Vaccine description
Target SARS-CoV-2
Vaccine type Inactivated
Clinical data
Other namesBIV1-CovIran [1]
COVIran Barakat
COVIran Barkat
کووایران برکت
Routes of
administration
Intramuscular
ATC code
  • None
Legal status
Legal status
  • Emergency use authorization: IRN

Full and emergency authorizations

Full list of COVIran Barekat authorizations

COVIran Barekat [2] (Persian : کووایران برکت) is a COVID-19 vaccine developed in Iran by Shifa Pharmed Industrial Group, a subsidiary of the Barkat Pharmaceutical Group. [3] [4] [5] It is an inactivated virus-based vaccine. [2] Iranian authorities have authorized its emergency use. This makes it the first locally developed COVID-19 vaccine to be approved for emergency use in the Middle East. [6]

Contents

Officials in charge say they are in the process to publish the results of the clinical trials in a peer-reviewed journal. [7] The interim results of the phases 1 and 2 trials showed 93.5% (95% CI, 88.499.6%) of the receivers of the vaccine have produced neutralizing antibodies against SARS-CoV-2. [8] Those results have not been peer-reviewed and describe the immunogenicity of the vaccine and not its efficacy. On 3 March 2022, peer-reviewed results have been published in the Clinical Microbiology and Infection. [9] [ further explanation needed ]

As of February 27, 2022, approximately 60 million doses have been produced according to Shifa Pharmed's CEO. [10] and the annual production capacity of this vaccine has reached 350 million doses. [11] Multiple Iranian personalities have received the vaccine, including the Supreme Leader, Ali Khamenei [4] and the President, Ebrahim Raisi. [12]

A version of the vaccine based on the Omicron variant and named CovIran Barkat Plus is in development and studied to be given as a third dose. [13] [14]

Medical uses

It is given by intramuscular injection and requires two doses given 28 days apart. [15]

Pharmacology

COVIran Barekat is an inactivated virus-based vaccine. [2] [16] In other words, "it is made of a coronavirus that has been weakened or killed by chemicals, similar to how polio immunizations are made". [17]

Developers

The Execution of Imam Khomeini's Order (EIKO) and Barkat Pharmaceutical Group is parent company of Shifa Pharmed Industrial Group. It's reported to be "state-affiliated". [4] Shifa Pharmed products include seven drugs and three biologics besides their COVID-19 vaccine which is their first vaccine to be produced. [18] Around 650 people worked in three shifts, around the clock, to develop the vaccine. [19]

Dr. Minoo Mohraz has been selected as the lead of the "Corona vaccine project in Iran". [20] Mohraz is an Iranian physician, scientist, and AIDS specialist. She is a full professor (emeritus) of infectious diseases at Tehran University of Medical Sciences and head of the Iranian Centre for HIV/AIDS. [21] Mohraz has also served, within the World Health Organization, as an expert on HIV/AIDS in Iran and the Eastern Mediterranean. [22]

Manufacturing

First production line, March 2021. COVIran Barekat vaccine production 03.jpg
First production line, March 2021.

Barkat Pharmaceutical Group started constructing a factory for vaccine production on 17 December 2020 [7] with the goal to build it in 3 months. [16] According to Execution of Imam Khomeini's Order (EIKO), under the direct control of the Supreme Leader of Iran, "production of the vaccine developed by one of its companies, Shifa Pharmed, could reach 12 million doses per month, six months after a successful trial ends". [23]

Mass production began on 15 March 2021. [24] [25] The first produced batch was unveiled on 10 May 2021. [26] [27]

There are three production lines for COVIran Barekat. [28] [7]

By 3 July 2021, about 2.7 million doses of COVIran Barekat vaccine had been produced and 400,000 doses had been delivered to the Iranian Ministry of Health, according to Mohammad Mokhber, the Deputy Coordinator of the Execution of Imam Khomeini's Order. [30]

By 27 July 2021, about 5 million doses had been produced and 1.3 million had been delivered to the Ministry of Health, according to Mokhber. [31]

By 30 August 2021, about 8 million doses had been produced and 4.2 million had been delivered to the Ministry of Health, according to EIKO. [32]

By 10 October 2021, about 16 million doses have been produced and 7.5 million had been delivered to the Ministry of Health, according to Shifa Pharmed's CEO. [33]

By 26 February 2022, about 60 million doses have been produced, according to Shifa Pharmed's CEO. [10]

History

Preclinical trials

The results of the preclinical study conducted on animals have been published in a preprint (not peer reviewed) on 10 June 2021. [34] According to the developers of the vaccine, trials showed that the vaccine was safe and effective in animals. [34]

On 26 October 2021, the results of the preclinical study have been published in the peer-reviewed Journal of Medical Virology. [1]

Clinical trials

Iran's first domestic COVID-19 vaccine candidate started clinical trials in late December 2020. Coviran barakat vaccine.jpg
Iran's first domestic COVID-19 vaccine candidate started clinical trials in late December 2020.
Vaccines for clinical trials. COVIran Barakat VACCINE.jpg
Vaccines for clinical trials.

Clinical trials are tests done in humans, to see whether a treatment is safe and effective. There are different phases of clinical research, and each phase has its own primary focus. For example, the focus of Phase I clinical trials is basic safety and dose information. All studies were randomized, double-blind, parallel arms, placebo-controlled and have been conducted on healthy volunteers. [35] [36] [15]

Clinical trials of COVIran Barekat vaccine
PhaseRegistrationNumber of participantsAge of participantsRef
NumberDateTotalVaccinePlaceboRatio

vaccine/

placebo

Trials on adults
I IRCT20201202049567N1 15 December 20205624 (3 μg)

24 (5 μg)

87:118-50 years [35]
IRCT20201202049567N2 13 March 2021322483:151-75 years [36]
II IRCT20201202049567N3 13 March 2021280224565:118-75 years [15] [37]
III21 April 202120,00013,3336,6662:1
Trials on children
I IRCT20171122037571N3 11 November 2021603030 (Sinopharm BIBP vaccine)1:112-18 years [38]
II440220220 (Sinopharm BIBP vaccine)1:1

Phase I

Iran Food and Drug Administration has approved the vaccine for testing on humans. [39] [40] [41] According to reports, more than 65,000 Iranians volunteered to test the vaccine while only 56 people were needed. [3]

On 29 December 2020, human trials of Iran's first domestic COVID-19 vaccine candidate were started. [3] [17] The first volunteer who received a shot of COVIran Barekat was Tayyebeh Mokhber, the daughter of Mohammad Mokhber, director of Setad. [3] Minister of Health Saeed Namaki and Vice President for Science and Technology Sorena Sattari participated at the ceremony of vaccine injection.

Phase 1's primary outcome was safety assessment. [8] A first phase 1 study was conducted on 56 healthy volunteers who were at the age of 18–50. [42] [43] [44] [35] Last injections of the second doses occurred on 4 March 2021. [8] A second phase 1 study was conducted on 32 volunteers aged 51-75 years. [36] First injections occurred on March 15 and last injections on April 9. [8]

Phase II/III

COVIran Barekat -- Phases II and III of the clinical trials COVID-19 vacir.jpg
COVIran Barekat -- Phases II and III of the clinical trials

Phases II and III of the clinical trials were combined, [45] [46] allowing to start the third phase before the second completed. Participants were aged between 18 and 75 years. [15]

Phase 2's primary outcome was immunogenicity assessment. [8] It was conducted on 280 volunteers. [15] The first volunteers were inoculated on March 15 [45] and the last injections of the second doses occurred on May 25. [8]

Phase 3's primary outcome was efficacy assessment on preventing mild, moderate and severe disease. [8] It was conducted on 20,000 participants [15] across 6 cities in Iran (Tehran, Karaj, Shiraz, Isfahan, Mashhad and Bushehr). [46] Phase III has been reached on April 21; [37] and the first injections occurred on April 25. [47] Up to June 14, 18,000 volunteers received their first dose and 2,000 received their second dose of the vaccine or placebo. [8] Dr. Minoo Mohraz was the first volunteer of the phase 3 that received the vaccine. [48]

Results

On 16 June 2021, a summary of the results obtained in the phase 1 and phase 2 of the clinical trials have been published in the press. [49] [50] According to the report, only mild adverse effects were registered execept one case of hypotension, one case of level-2 headache and one case of diminution of platelets that didn't need medical care. [8] Conventional Virus Neutralizing Test (cVNT) is reported to have shown 93.5% immunogenicity (95% confidence interval: 88.4 – 99.6%). [8] On 23 June 2021, the production project manager of the vaccine stated that the results of the second phase have shown "the serum of the people who received the vaccine has 93.5% power to neutralize the virus; thus meaning the vaccine has a very good efficacy that will be shown after the end of the third phase". [51]

There are claims of some issues with the vaccine's scientific documentation article according to the U.S. Agency for Global Media-owned broadcasting network Radio Farda, [52]

On 27 July 2021, the Director of the Barkat Pharmaceutical Group stated that a paper with the result of the clinical trials have been prepared and submitted. "It will be sent to 10 important scientific journals of the world but it may take time before they publish it". [7]

In February 2021 (while phase 1 study was ongoing), the head of the vaccine production team at the Setad stated that the vaccine also neutralizes the British mutated COVID-19 virus. [53] [54] [55]

On 3 March 2022, clinical results have been published in Clinical Microbiology and Infection, a peer-reviewed medical journal. [9]

On 9 April 2022, peer-reviewed results of the phases I and II of the clinical trials have been published in BMJ Open. [56] [ further explanation needed ]

Trial on children aged 12-18

A phase I-II clinical trial on children aged 12-18 years began on 23 November 2021. [57] [38] It consist of a comparison study where half of the 500 participants receive a Coviran Barkat vaccine and the other half a Sinopharm BIBP vaccine. Primary outcome is safety and immunogenicity assessment. [38]

Other countries

As official in charge of manufacturing Iran Barekat vaccines, Mohammad Reza Salehi said, "some neighboring countries tend to enter the third phase of the clinical trial of the Iranian COVIran Barekat". They are reviewing recommendations to let them participate. [42] on 17 march 2022 Iran signed an agreement with Nicaragua to export this vaccine. [58] [59]

Authorizations

The vaccine received its authorization license from the Iran Food and Drug Administration on June 13, 2021. [60]

CovIran Barkat is in the process to be registered by the World Health Organization. [61] Presubmission meeting held on 26 January 2022. [62] [63]

Society and culture

Ali Khamenei, the Supreme Leader of Iran, received his first dose of Iran's locally made COVIran Barekat vaccine on 25 June 2021 (twelve days after it received its public use authorization from Iranian authorities). [4] [64] [65] He received his second dose on 23 July 2021. [66]

Ebrahim Raisi, [67] [12] Mohammad Bagher Ghalibaf, [68] Ali Larijani, [69] and Amoli Larijani, [70] have been vaccinated with COVIran Barekat.

CovIran Barkat Plus

CovIran Barkat Plus (also named BIV1-CovIran Plus) is a COVID-19 vaccine candidate based on the Omicron variant. [13] [71] It is currently in development and studied as a third dose. [14]

On 15 February 2022, preprint of the results of the preclinical studies conducted on animals have been published in BioRxiv. [71] [72] Clinical trials on humans began in March 2022 after the Ministry of Health and Medical Education (of Iran) gave its approval following the studies on animals. [13] [73] [10] [74] Clinical trials are conducted on 210 volunteers with a history of two-dose vaccination of either the standard CovIran Barkat or the Sinopharm BIBP vaccine. CovIran Barkat Plus will be given as a third dose. [14]

See also

Related Research Articles

Execution of Imam Khomeinis Order

The Execution of Imam Khomeini's Order (EIKO),, also known as the Executive Headquarters of Imam's Directive or simply Setad, is a parastatal organization in the Islamic Republic of Iran, under direct control of the Supreme Leader of Iran. It was created from thousands of properties confiscated in the aftermath of the 1979 Islamic Revolution. A Reuters investigation found that the organization built "its empire on the systematic seizure of thousands of properties belonging to ordinary Iranians", also seizing property from members of religious minorities, business people and Iranians living abroad; at times falsely claiming that the properties were abandoned.

Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden and Vienna, Austria, with other offices in France, Canada and the United States.

Barakat Foundation

The Barakat Foundation is a charitable trust in Iran focused on economic development projects in rural areas. It has also stakes in Iran’s pharmaceutical industry. It's affiliated to the Execution of Imam Khomeini's Order which is controlled by Seyyed Ali Khamenei.

Barkat Pharmaceutical Group Iranian pharmaceutical group

Barkat Pharmaceutical Group is an Iranian Pharmaceutical public company, which was founded in 2010, named Tadbir innovation pharmaceutical company. The company provides services through cooperation between science-based institutions and scientists based on medicine around the world. It supplies 14 percent of all the country's essential drugs through its 25 subsidiaries. The company produces 700 kinds of products in the pharmaceutical sector and offers it internally. The Barkat Pharmaceutical Group has established as the first specialized drug and pharmaceutical research center in Iran, also it has been developed by constructing advanced pharmaceutical factories, called Barkat Pharmaceutical Town. The Barkat group complies with all common pharmaceutical standards such as the FDA, WHO, EMEA. "Cell therapy", production of "peptide medications", "research, development and processing of medicinal plants," the creation of the "Museum of Iranian-Islamic Medicine" as well as "Solids and Semi-Solids" projects are the main activities of the Group.

Convidecia Vaccine against COVID-19

AD5-nCOV, trade-named Convidecia, is a single-dose viral vector vaccine for COVID-19 developed by CanSino Biologics. It conducted its Phase III trials in Argentina, Chile, Mexico, Pakistan, Russia, and Saudi Arabia with 40,000 participants.

Barkat Ventures is an Iranian knowledge-based institute which has been established as the arm of the Imam (Khomeini)'s Command's Executive in order to develop knowledge-based economy. This institute's mission is to create and expand on the ecosystem/infrastructure for the development of science and knowledge-based activities of the scholars in Iran on the basis of Islamic-Iranian models by utilizing Iranian scientists, experts, global-experience, knowledge and so on.

Valneva COVID-19 vaccine Vaccine candidate against COVID-19

Valneva COVID-19 vaccine, also known as the VLA2001 and VLA2101 , is a COVID-19 vaccine candidate developed by French biotechnology company Valneva SE in collaboration with American company Dynavax Technologies. On 14 April 2022, the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved the vaccine, being the first in the world to do so.

Soberana 02 Vaccine against COVID-19

Soberana 02 or Soberana 2, technical name FINLAY-FR-2, is a COVID-19 vaccine produced by the Finlay Institute, a Cuban epidemiological research institute. The vaccine is known as PastoCovac in Iran, where it has been developed in collaboration with the Pasteur Institute of Iran.

ZyCoV-D Vaccine candidate against COVID-19

ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council. It is approved for emergency use in India.

SCB-2019 Vaccine candidate against COVID-19

SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. Positive results of Phase I trials for the vaccine were published in The Lancet and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021. In September 2021, SCB-2019 announced Phase III results showing 67% efficacy against all cases of COVID-19 and 79% efficacy against all cases of the Delta variant. Additionally, the vaccine was 84% effective against moderate cases and 100% effective against hospitalization.

Sinopharm WIBP COVID-19 vaccine Vaccine against COVID-19

The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases. The other inactivated virus COVID-19 vaccine developed by Sinopharm is the BIBP vaccine (BBIBP-CorV) which is comparably more successful. 1 billion doses are expected to be produced per year.

MVC COVID-19 vaccine Vaccine against COVID-19

The MVC COVID-19 vaccine, designated MVC-COV1901 and also known as the Medigen COVID-19 vaccine, is a protein subunit COVID-19 vaccine developed by Medigen Vaccine Biologics Corporation in Taiwan, American company Dynavax Technologies, and the U.S. National Institutes of Health.

Corbevax Vaccine against COVID-19

Corbevax is a protein subunit COVID-19 vaccine developed by Texas Children's Hospital Center for Vaccine Development and Baylor College of Medicine in Houston, Texas and Dynavax technologies based in Emeryville, California. It is licensed to Indian biopharmaceutical firm Biological E. Limited (BioE) for development and production.

Razi Cov Pars Vaccine candidate against COVID-19

Razi Cov Pars is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute.

FAKHRAVAC Vaccine against COVID-19

FAKHRAVAC is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research, a subsidiary of Iran's Ministry of Defense. It's the third Iranian COVID-19 vaccine reaching clinical trials. It's currently in phase III. It has received emergency use authorization in Iran on 9 September 2021.

COVAX-19 Vaccine candidate against COVID-19

COVAX-19 is the result of a collaboration between Vaxine and CinnaGen, a private company with operations in the Middle East. COVAX-19 is a recombinant protein-based COVID-19 vaccine developed by South Australian-based biotech company Vaxine. It is under clinical trial in collaboration with the Iranian company CinnaGen.

ARCT-154 Vaccine candidate against COVID-19

ARCT-154, also known as VBC-COV19-154 in Vietnam, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics. For its development, Arcturus collaborated with Vinbiocare, a Vietnamese company, for support with clinical trials and manufacturing.

COVID-19 vaccine clinical research

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. Thirty vaccines are authorized for use by national governments, including eight approved for emergency or full use by at least one WHO-recognised stringent regulatory authority; while five are in Phase IV. 204 vaccines are undergoing clinical trials that have yet to be authorized. Nine clinical trials consider heterologous vaccination courses.

Noora (vaccine) Vaccine candidate against COVID-19

Noora is a COVID-19 vaccine candidate developed by Baqiyatallah University of Medical Sciences in Iran.

Soberana Plus Vaccine

Soberana Plus, technical name FINLAY-FR-1A, is a COVID-19 candidate vaccine produced by the Finlay Institute, a Cuban epidemiological research institute.

References

  1. 1 2 Abdoli, Asghar; Aalizadeh, Reza; Aminianfar, Hossein; Kianmehr, Zahra; Teimoori, Ali; Azimi, Ebrahim; Emamipour, Nabbi; Eghtedardoost, Marzieh; Siavashi, Vahid; Jamshidi, Hamidreza; Hosseinpour, Mohammadreza; Taqavian, Mohammad; Jalili, Hasan (26 October 2021). "Safety and potency of BIV1‐CovIran inactivated vaccine candidate for SARS‐CoV‐2: A preclinical study". Reviews in Medical Virology: e2305. doi:10.1002/rmv.2305. PMC   8646699 . PMID   34699647.
  2. 1 2 3 Mallapaty S (August 2021). "Iran hopes to defeat COVID with home-grown crop of vaccines". Nature. 596 (7873): 475. Bibcode:2021Natur.596..475M. doi:10.1038/d41586-021-02216-z. PMID   34404947. S2CID   237198729.
  3. 1 2 3 4 Motamedi M (29 December 2020). "COVIran Barakat: Iran launches human trials of its COVID vaccine". Al Jazeera. Archived from the original on 31 January 2021.
  4. 1 2 3 4 "Iran's leader gets locally made coronavirus vaccine shot". Reuters. 2021-06-25. Retrieved 2021-08-24.
  5. "About - شرکت گروه صنایع شفافارمد". 2021-04-15. Retrieved 2021-09-03.
  6. Baghishov E (14 June 2021). "Iran issues license on its coronavirus vaccine". Trend.Az. Archived from the original on 2021-06-14. Retrieved 14 June 2021.
  7. 1 2 3 4 5 6 7 "زیرساخت تولید ماهانه 25 تا 30 میلیون دوز واکسن برکت فراهم شده است + پاسخ به شبهات- اخبار پزشکی - اخبار اجتماعی تسنیم" [The infrastructure for the monthly production of 25 to 30 million doses of Barakat vaccine has been provided + Answering the suspicions - Medical news]. خبرگزاری تسنیم (Tasnim Social News) (in Persian). Retrieved 2021-08-24.
  8. 1 2 3 4 5 6 7 8 9 10 Setad (EIKO) (2021-06-16). "خلاصه نتایج تست انسانی واکسن کوو ایران برکت" [Summary of the results of COVIran Barekat vaccine's clinical trials](PDF). Archived from the original (PDF) on 2021-06-16. Retrieved 2021-09-05.
  9. 1 2 Salehi, Mohammadreza; Hosseini, Hamed; Jamshidi, Hamid Reza; Jalili, Hasan; Tabarsi, Payam; Mohraz, Minoo; Karimi, Hesam; Lotfinia, Majid; Aalizadeh, Reza; Mohammadi, Mehrdad; Ramazi, Shahin (2022-03-03). "Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern". Clinical Microbiology and Infection. doi:10.1016/j.cmi.2022.02.030. ISSN   1198-743X. PMC   8893932 . PMID   35248745.
  10. 1 2 3 "تولید ۶۰ میلیون دُز واکسن برکت در شفافارمد/ آغاز مطالعه بالینی واکسن اختصاصی اُمیکرون | خبرگزاری فارس" [Production of 60 million doses of Barakat vaccine in Shafafarmed / Initiation of clinical study of Omicron specific vaccine]. www.farsnews.ir (in Persian). 2022-02-26. Retrieved 2022-02-27.
  11. The production capacity of the Barakat vaccine reached 350 million doses per year Tasnimnews.com, Retrieved 26 April 2022
  12. 1 2 "دکتر رئیسی نخستین دُز واکسن کوو ایران برکت را دریافت کرد" [Dr. Raisi received the first dose of Iran-Barakat vaccine]. ایرنا (in Persian). 2021-08-08. Archived from the original on 2021-09-03. Retrieved 2021-09-03.
  13. 1 2 3 "Iranian-made vaccine against Omicron begins clinical trial". Tehran Times. 2022-03-02. Retrieved 2022-03-03.
  14. 1 2 3 "IRCT | A Clinical trial to evaluate the immunogenicity and safety of Omicron-Based CovIran Barkat vaccine as a third injection dose in vaccinated population over 18 years of age". en.irct.ir. Retrieved 2022-03-03.
  15. 1 2 3 4 5 6 "IRCT | A double-blind, randomized, placebo-controlled Phase II/III Clinical trial to evaluate the safety and efficacy of COVID-19 inactivated vaccine (Shifa-Pharmed) in a population aged 18 to 75 years". en.irct.ir. Iranian Registry of Clinical Trials (IRCT). Archived from the original on 2021-04-23. Retrieved 2021-04-07.
  16. 1 2 "COVID-19 Vaccine (pharmaceutical product)". شرکت گروه صنایع شفافارمد (Shafafarmad Industries Group Company). 2021-04-19. Retrieved 2021-08-09.
  17. 1 2 "Iran begins first human trial of locally made virus vaccine". health.economictimes.indiatimes. 29 December 2019. Archived from the original on 3 February 2021.
  18. "Growth Factor". شرکت گروه صنایع شفافارمد (Shafafarmad Industries Group Company). 2021-04-19. Retrieved 2021-08-09.
  19. "دانش فنی واکسن برکت صد درصد ایرانی است/ تلاش ۶۵۰ نفر در ساخت واکسن ایرانی کرونا" [Vaccine technical knowledge is 100% Iranian / 650 people participated in developing Iranian COVID-19 vaccine]. Tasnim News Agency (in Persian). Archived from the original on 9 July 2021. Retrieved 2021-06-26.
  20. Ardalan S (6 December 2020). "واکسن ایرانی کرونا تا 'تیر ماه آینده می‌رسد'" [Iranian corona vaccine will arrive by 'next July']. BBC News (in Persian). Archived from the original on 2020-12-06. Retrieved 2020-12-18.
  21. "Good News About AIDS". Young Journalists Club. February 6, 2016. Retrieved 2020-02-26.
  22. "علامه طباطبایی استاد مينو محرز: هرچه دارم از دانشگاه علوم پزشكي تهران است" [Allameh Tabatabai | Professor Minoo Mehrz: Everything I have is from Tehran University of Medical Sciences] (in Persian). Tehran University of Medical Sciences Alumni Communication Office. Archived from the original on May 19, 2021. Retrieved March 29, 2017.
  23. "Iran starts human testing of first domestic COVID-19 vaccine". Reuters. 29 December 2019. Archived from the original on 12 January 2021.
  24. "Iran starts mass-production of homegrown coronavirus vaccine". Tehran Times. 2021-03-15. Archived from the original on 2021-03-22. Retrieved 2021-04-07.
  25. "اولین تصاویر از خط تولید واکسن کووایران برکت". setad.ir (in Persian). 2021-03-15. Retrieved 2021-09-01.
  26. "رونمایی ازمحموله تولید انبوه واکسن «کوو ایران برکت»". setad.ir (in Persian). 2021-05-11. Retrieved 2021-09-01.
  27. "نخستین محصول تولید انبوه واکسن "کوو ایران برکت" فردا رونمایی می‌شود" [The first mass-produced product of "Koo Iran Barakat" vaccine will be unveiled tomorrow]. irna (in Persian). 10 May 2021. Archived from the original on 17 May 2021. Retrieved 26 June 2021.
  28. 1 2 3 4 "فاز یک خط تولید واکسن برکت". setad.ir (in Persian). 2021-08-14. Retrieved 2021-09-01.
  29. "Iran to kick off production of 3mn doses of COVIRAN". Mehr News Agency. 2021-03-15. Archived from the original on 2021-03-15. Retrieved 2021-04-07.
  30. "ببینید | تحویل 50 میلیون دُز واکسن «کوو ایران برکت» تا پایان شهریور - خبرآنلاین". www.khabaronline.ir. 2021-07-03. Archived from the original on 2021-08-13. Retrieved 2021-08-29.
  31. "افتتاح اولین صندوق قرض‌الحسنه اشتغال کشور توسط ستاد اجرایی فرمان امام/ تولید 5 میلیون واکسن «برکت» تاکنون" [Inauguration of the first loan fund of the country by the executive headquarters of Farman Imam / Production of 5 million "Barakat" vaccines so far]. farsnews.ir (in Persian). Retrieved 27 July 2021.
  32. "تعداد واکسن‌های تولید شده کوو ایران برکت به ۸ میلیون دز رسید". خبرگزاری موج (in Persian). 2021-08-30. Archived from the original on 2021-09-04. Retrieved 2021-09-08.
  33. "تولید 16 میلیون دوز واکسن برکت تا امروز/ ارائه مستندات برای اخذ مجوز سازمان جهانی بهداشت- اخبار پزشکی - اخبار اجتماعی تسنیم | Tasnim". خبرگزاری تسنیم | Tasnim (in Persian). Retrieved 2021-11-27.
  34. 1 2 Abdoli A, Aalizadeh R, Aminianfar H, Kianmehr Z, Azimi E, Emamipour N, et al. (January 2021). "Safety and Potency of COVIran Barekat Inactivated Vaccine Candidate for SARS-CoV-2: A Preclinical Study". bioRxiv   10.1101/2021.06.10.447951 .
  35. 1 2 3 "IRCT | A double-blinded, randomized, placebo-controlled Phase I Clinical trial to evaluate the safety and immunogenicity of COVID-19 inactivated vaccine (Shif-Pharmed) in a healthy population". en.irct.ir. Retrieved 2021-08-27.
  36. 1 2 3 "IRCT | A double-blind, randomized, placebo-controlled Phase I Clinical trial to evaluate the safety and immunogenicity of COVID-19 inactivated vaccine (Shifa-Pharmed) in a healthy population aged 51-75 years". en.irct.ir. Retrieved 2021-08-27.
  37. 1 2 "آغاز مرحله سوم تست انسانی کووایران برکت" [The beginning of the third stage of the human test of COVIran Barakat]. Islamic Republic of Iran News Network (in Persian). Archived from the original on 2021-06-26. Retrieved 21 April 2021.
  38. 1 2 3 "IRCT | Comparison of the tolerability, safety, and immunogenicity of Shifa-Pharmed COVID-19 inactivated vaccine (CovIran) and Sinopharm vaccine in the healthy population aged 12 to 18 years: a double-blind, randomized, active-controlled, Phase I-II clinical trial". en.irct.ir. Retrieved 2021-11-27.
  39. Bulos N (19 January 2021). "Iranians demand a COVID-19 vaccine, not politics, from their leaders". Los Angeles Times . Archived from the original on 2021-01-19.
  40. Khoshhal P (21 January 2021). "Coronavirus Tzar Forced to Apologize to Clergy". iranwire. Archived from the original on 2021-01-21.
  41. Vahdat A (29 December 2020). "Iran begins human trials for locally made coronavirus vaccine". Times of Israel. Archived from the original on 16 January 2021. Retrieved 30 December 2020.
  42. 1 2 "Some foreign states willing to cooperate in COVIran Barakat clinical test: Official". irna. 30 March 2021. Archived from the original on 2021-03-31. Retrieved 2021-04-07.
  43. "تست انسانی واکسن ایرانی کرونا آغاز شد/ وزیر بهداشت: ما با ۱۰۰ سال سابقه، اولین واکسن‌ساز آسیا هستیم" [Human test of Iranian corona vaccine begins / Minister of Health: We are the first vaccinator in Asia with 100 years of experience]. Tasnim News Agency (in Persian). Archived from the original on 26 June 2021.
  44. "پایان تزریق فاز یک مطالعات واکسن کووایران برکت" [End of the injection of phase one (studies) of "Kovoo-Iran Barakat" vaccine]. Young Journalists Club (in Persian). Archived from the original on 14 July 2021. Retrieved 16 February 2021.
  45. 1 2 "Clinical trials of COVIRAN vaccine enter phases 2, 3". Iranian Students News Agency. 15 March 2021. Archived from the original on 11 May 2021. Retrieved 8 April 2021.
  46. 1 2 "واکسن ایران برکت احتمالا تا پایان خرداد ۱۴۰۰ به دست هموطنان می‌رسد" [Iran Barakat vaccine will probably reach our compatriots by the end of June 1400]. Iranian Students News Agency (in Persian). 24 March 2021. Archived from the original on 26 June 2021.
  47. "تزریق فاز سوم واکسن کوو ایران برکت انجام شد" [The third phase of Iran Barakat vaccine was injected]. Young Journalists Club (in Persian). Archived from the original on 26 June 2021. Retrieved 25 April 2021.
  48. "دکتر محرز واکسن کووایران برکت تزریق کرد". ایرنا (in Persian). 2021-04-25. Archived from the original on 2021-04-26. Retrieved 2021-09-09.
  49. "جزئیات مطالعه بالینی واکسن "کووایران برکت" منتشر شد + نتایج". ایسنا (in Persian). 2021-06-16. Retrieved 2021-08-31.
  50. "انتشارخلاصه نتایج تست انسانی واکسن کوو ایران برکت برای نخستین‌بار". setad.ir (in Persian). 2021-06-16. Retrieved 2021-08-31.
  51. "ایمنی‌زایی ۹۳.۵درصدی واکسن برکت در فاز دوم/ ۱۲ کشور برای خرید درخواست دادند" [93.5% immunity for Barakat vaccine in Phase II / 12 countries apply for purchase]. Tasnim News Agency (in Persian). Retrieved 24 June 2021.
  52. "خامنه‌ای پس از دریافت "واکسن ایرانی کرونا": واکسن خارجی هم ایرادی ندارد" [Khamenei after receiving the "Iranian corona vaccine": There is no problem with the foreign vaccine]. رادیو فردا (in Persian). Archived from the original on 2021-06-26. Retrieved 2021-06-26.
  53. "جلیلی: واکسن کوو ایران برکت، ویروس انگلیسی را خنثی می‌کند" [Jalili: The Iranian vaccine neutralizes the British virus]. Young Journalists Club (in Persian). Archived from the original on 26 June 2021.
  54. "موفقیت واکسن ایرانی در خنثی کردن "ویروس جهش‌یافته انگلیسی"" [Iranian vaccine succeeds in neutralizing "British mutated virus]. Iranian Students News Agency (in Persian). Archived from the original on 26 June 2021.
  55. Haghdoost H (17 February 2021). "Iran Vaccine Boasts Total Protection Against U.K. Covid Strain". bloomberg. Archived from the original on 2021-04-15. Retrieved 2021-04-08.
  56. Mohraz, Minoo; Salehi, Mohammadreza; Tabarsi, Payam; Abbasi-Kangevari, Mohsen; Ghamari, Seyyed-Hadi; Ghasemi, Erfan; Pouya, Maryam Amini; Rezaei, Negar; Ahmadi, Naser; Heidari, Kazem; Malekpour, Mohammad-Reza (2022-04-01). "Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults". BMJ Open. 12 (4): e056872. doi:10.1136/bmjopen-2021-056872. ISSN   2044-6055. PMC   8995575 . PMID   35396297.
  57. "COVIRAN begins clinical trial on children aged 12-18". Tehran Times. 2021-11-23. Retrieved 2021-11-27.
  58. "COVIran Barekat to be exported to Nicaragua". iranpress.com. Retrieved 2022-03-17.
  59. https://www.efe.com/efe/america/sociedad/iran-dona-a-nicaragua-200-000-dosis-de-vacunas-contra-la-covid-19/20000013-4764787
  60. "مجوز مصرف واکسن "کووایران برکت" صادر شد" [The license to use the "Kovairan Barakat" vaccine was issued]. Young Journalists Club (in Persian). Archived from the original on 26 June 2021. Retrieved 16 June 2021.
  61. "COVIRAN BAREKAT in process to WHO's registration". Tehran Times. 2021-07-25. Retrieved 2021-08-04.
  62. "Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process". 2 March 2022. Retrieved 2022-03-03.
  63. "COVIRAN vaccine begins global registration process". Tehran Times. 2022-01-28. Retrieved 2022-03-03.
  64. "FarsNews Agency Ayatollah Khamenei Receives Iran-Made Coronavirus Vaccine". www.farsnews.ir. 2021-06-25. Archived from the original on 2021-06-25. Retrieved 2021-09-03.
  65. Motamedi M (2021-06-21). "Iran's Supreme Leader Khamenei receives local COVID vaccine". www.aljazeera.com. Archived from the original on 2021-06-25. Retrieved 2021-09-04.
  66. "Leader receives second dose of Iranian COVID-19 vaccine". ISNA. 2021-07-23. Retrieved 2021-09-03.
  67. "Iran records over 500 Covid deaths, hits new high". France 24. 2021-08-08. Retrieved 2021-09-04.
  68. "قالیباف واکسن برکت دریافت کرد" [Qalibaf received the blessed vaccine]. ایسنا (in Persian). 2021-08-07. Retrieved 2021-09-03.
  69. "علی لاریجانی واکسن ایرانی تزریق کرد" [Ali Larijani is injected with the Iranian vaccine]. جامعه خبری تحلیلی الف (in Persian). 2021-08-03. Archived from the original on 2021-08-04. Retrieved 2021-09-03.
  70. "عکس/ تزریق واکسن برکت به آملی لاریجانی" [Blessed vaccine injection to Amoli Larijani]. مشرق نیوز (in Persian). 2021-08-04. Retrieved 2021-09-03.
  71. 1 2 "CovIran Plus elicits protective neutralization against Omicron: study". Tehran Times. 2022-02-16. Retrieved 2022-03-03.
  72. Abdoli, Asghar; Khanali, Javad; Azangou-Khyavy, Mohammadreza; Abbasi-Kangevari, Mohsen; Ghamari, Seyyed-Hadi; Malekpour, Mohammad-Reza; Jamshidi, Hamidreza; Taqavian, Mohammad; Baghal, Mehdi Lari; Jalili, Hasan (2022-02-15). "Omicron-Based Vaccine Candidate Elicits Potent Neutralizing Antibodies in the Animal Model": 2022.02.11.480131. doi:10.1101/2022.02.11.480131. S2CID   246905534.{{cite journal}}: Cite journal requires |journal= (help)
  73. "خبرگزاری فارس - آغاز کارآزمایی بالینی واکسن برکت پلاس". خبرگزاری فارس. 2022-03-02. Retrieved 2022-03-03.
  74. Omicron-specific Barkat vaccine was developed IRNA, Retrieved 6 March 2022